Datapoint: Lilly Scores First-Ever Alopecia Areata Nod

With this week’s FDA approval, Eli Lilly and Incyte’s Olumiant is first-ever treatment for alopecia areata, an autoimmune disease that causes a severe form of hair loss. The JAK inhibitor was first approved in 2018 as a rheumatoid arthritis therapy. For the treatment of rheumatoid arthritis, Olumiant holds covered or better status for 61% of all insured lives. Just 11% of insured lives have preferred access to Olumiant.

SOURCE: MMIT Analytics, as of 6/15/22

0

0

0 Comments

0

0

• Datapoint